REGN beat EPS expectations by 9.48%
Apr 29, 2025, 10:32 PM
0.00%
What does REGN do
Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
Regeneron Pharmaceuticals (REGN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Regeneron Pharmaceuticals's actual EPS was $8.22, beating the estimate of $9.00 per share, resulting in a 9.48% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.